Kythera Biopharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Kythera Biopharmaceuticals sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Kythera Biopharmaceuticals: 19 sponsored US clinical trials, none currently recruiting.
Kythera Biopharmaceuticals sponsors 19 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 19 completed. 7 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 2 trials.
Top-decile sponsor footprint
Kythera Biopharmaceuticals ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
19 total, page 1 of 1
Condition of Submental Fullness and Treatment Outcomes Registry
NCT02438813
Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age
NCT02123134
Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat
NCT02035267
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
NCT02163902
Patient Experience Study of Deoxycholic Acid Injection
NCT02007434
Evaluation of the Effect of ATX-101 on QT/QTc Intervals
NCT01706679
Open-Label Pharmacokinetic Study of Final Formulations of ATX-101
NCT01632917
Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
NCT01546142
Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
NCT01542034
To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101
NCT01462786
Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area
NCT01426373
Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue
NCT01319916
Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study
NCT01032889
Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
NCT02159729
ATX-101 Abdominoplasty
NCT00835952
Dose-Escalation Safety and Pharmacokinetic Study of ATX-101
NCT00618709
Phase 2 Study for the Treatment of Superficial Lipomas
NCT00608842
Deoxycholic Acid Injection for the Treatment of Superficial Lipomas
NCT00422188
A Study to Assess Injection Comfort of Two Formulations of ATX-101
NCT01320761
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 3 |
| Phase 3 | 7 |
Therapeutic Areas
How the Kythera Biopharmaceuticals early-phase archive is shaped
19 indexed studies, none listed as recruiting (0% open); 19 completed (100%).
Phase mix: 7 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Healthy (2 trials), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Kythera Biopharmaceuticals: archived-pipeline peers nationwide
Peers matched on 19 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Kythera Biopharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 archived trials
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Kythera Biopharmaceuticals page
19 registered trials is a research-attention snapshot, not an endorsement of Kythera Biopharmaceuticals or any single study.
- None of Kythera Biopharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy is the condition Kythera Biopharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kythera Biopharmaceuticals pipeline card: 19 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.